IGF1 and acromegaly: In this 36-week, Phase IIIb study (clinicaltrials.gov ID: NCT02354508), we evaluated the efficacy—according to the strict criteria for biochemical control recommended in current treatment guidelines (GH <1 μg/L and IGF-I <ULN) (4)—and safety of long-acting pasireotide in patients with uncontrolled acromegaly despite ≥3 months of treatment with maximal approved doses of first-generation SSAs.